Education
About Us
Working with TipRanks
Follow Us
Talphera (TLPH)
NASDAQ:TLPH
Earnings Data
Report Date
May 19, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.17Last Year’s EPS
-0.16Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 31, 2025
|% Change Since: 0.00%
|Next Earnings Date:May 19, 2025
Earnings Call Sentiment|Positive
The earnings call detailed significant progress, including FDA approvals and financial backing, improving the outlook for the NEPHRO CRRT study. However, challenges with initial study sites and uncertainty regarding enrollment timelines were noted.Company Guidance
During the Talphera Fourth Quarter and Full Year 2024 Financial Results Conference call, significant updates were provided regarding the NEPHRO CRRT study. The company anticipates completing this study by the end of 2025, with an FDA submission for Niyad expected in the first quarter of 2026. A major highlight was the FDA's approval to reduce the trial size from 166 to 70 patients while retaining a 90% power for the primary endpoint. Talphera also secured a private placement investment of up to $14.8 million, structured in three tranches tied to patient enrollment milestones and stock performance. The company aims to achieve 13 enrollment-ready sites by mid-2025, with new protocol changes expected to accelerate patient enrollment. Talphera reported a decrease in combined R&D and SG&A expenses to $3 million for Q4 2024, down from $4.6 million in Q4 2023, and plans to maintain cash operating expenses in the range of $18 million to $19 million for 2025.Successful FDA Approvals
The FDA approved a reduction in the NEPHRO CRRT study size from 166 patients to 70, while maintaining 90% power for the primary endpoint. Additionally, two major protocol changes were approved, improving patient enrollment criteria.
Private Placement Investment Secured
Talphera secured a private placement investment of up to $14.8 million, contingent on achieving certain milestones, providing necessary capital for the NEPHRO study completion.
Reduction in Operating Expenses
Operating expenses were reduced, with combined R&D and SG&A expenses for Q4 2024 totaling $3 million, down from $4.6 million in Q4 2023.
Expansion of Enrollment-Ready Sites
Talphera increased enrollment-ready sites to eight, with plans to reach 13 by mid-year 2025, potentially increasing patient enrollment rates.
---
TLPH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TLPH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 31, 2025 | $0.50 | $0.53 | +6.00% |
| Nov 13, 2024 | $0.89 | $0.66 | -25.84% |
| Aug 14, 2024 | $0.86 | $0.87 | +1.16% |
| May 14, 2024 | $1.02 | $1.22 | +19.61% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Talphera (TLPH) report earnings?
Talphera (TLPH) is schdueled to report earning on May 19, 2025, TBA Not Confirmed.
What is Talphera (TLPH) earnings time?
Talphera (TLPH) earnings time is at May 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TLPH EPS forecast?
TLPH EPS forecast for the fiscal quarter 2025 (Q1) is -0.17.
---